IL1B and inflammatory bowel disease: Patients with CARD8 loss-of-function mutation specifically responded to IL1β blockers, but not to anti-TNFα (Mao et al., 2018), demonstrating the role of CARD8-NLRP3-IL1β axis in IBD.